HOME PAGE > La actualidad de Chiesi

La actualidad de Chiesi

-
30/01/2020
-
See more
 
-
21/02/2019
-
See more
 
-
16/11/2018
-
See more
-
26/04/2018
-
See more
 
-
26/04/2018
-
See more
 
-
26/04/2018
-
See more
-
13/04/2018
-
See more
 
Chiesi Group receives the European Marketing...
04/04/2018
  Lamzede® (velmanase alfa) is the first enzyme replacement therapy for the treatment of non-neurological...
See more
 
Chiesi Spain and Richi Entrepreneurs launch the...
22/03/2018
-
See more
-
18/03/2018
-
See more
 
-
13/03/2018
-
See more
 
-
07/03/2018
-
See more
-
22/02/2018
-
See more
 
New study published in The Lancet shows Trimbow®...
12/02/2018
  The TRIBUTE study showed superiority of Chiesi’s triple extrafine formulation Trimbow® over Ultibro®...
See more
 
Chiesi Group receives positive opinion from CHMP...
29/01/2018
Lamzede® (velmanase alfa) is the first pharmacological therapy for the treatment of Alpha Mannosidosis, an ultra-rare,...
See more
"Internal entrepreneurs are key to the evolution...
23/01/2018
Thanks to intrapreneurship, the organization's culture can be developed by innovative ideas or projects while increasing...
See more
 
Chiesi leads the ranking of italian companies...
02/01/2018
  The EU Industrial R & D Investment Ranking of the European Commission in 2017 places the Chiesi Group at the top of...
See more
 
Balanced nutrition helps prevent decompensation...
21/12/2017
-
See more
Reducing the risk of long-term rejection is the...
19/12/2017
-
See more
 
-
30/11/2017
-
See more
 
-
30/11/2017
-
See more
-
28/11/2017
-
See more
 
"TRANSPLANTATION IN ACTION" ALLOWS MORE THAN 70...
27/11/2017
With 65 donors per million population, Spain leads the world ranking of kidney transplants and in 2017 hopes to once again beat...
See more
 
-
03/11/2017
-
See more
CHIESI ENTERS INTO AN EXCLUSIVE EX-US PARTNERSHIP...
25/10/2017
    Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein...
See more
 
-
17/10/2017
Concepción Berdala, Deputy Director of Nursing, Santiago Artillo, Deputy Medical Director of the Maternal and Child Health...
See more
 
-
07/09/2017
-
See more
Chiesi Group receives the European Marketing...
24/07/2017
Chiesi Group receives the European Marketing Authorisation for Trimbow® (ICS/LABA/LAMA)     Parma, Italy July...
See more
 
Chiesi Farmaceutici completes the acquisition of...
23/06/2017
Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate)...
See more
 
-
01/06/2017
-
See more
Respiration Day 2017
28/05/2017
 The present and future of chronic obstructive pulmonary disease is the focus of the Respiration Day 2017: from the new GOLD...
See more
 
"Between 10-15% of cases of asthma in adults can...
24/05/2017
This type of asthma has become the most common occupational lung disease in developed countries1  It is due to the...
See more
 
-
22/05/2017
       
See more
-
17/05/2017
-
See more
 
-
08/05/2017
-
See more
 
Chiesi Group reports an increased turnover in...
26/04/2017
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence     Chiesi Group closes...
See more
GLYBERA▼ (ALIPOGENE TIPARVOVEC) IN EUROPE
20/04/2017
GLYBERA▼ (ALIPOGENE TIPARVOVEC) IN EUROPE   Parma, 20 April 2017 - Chiesi Farmaceutici Spa (“Chiesi”)...
See more
 
-
04/04/2017
-
See more
 
-
29/03/2017
-
See more
Chiesi and Molecular Warehouse join forces to...
28/02/2017
London, February 28, 2017 – Chiesi Farmaceutici Spa (“Chiesi”), an international research-focused Healthcare...
See more
 
Chiesi grants the startup New Born Solutions to...
11/01/2017
  Barcelona, 11th January, 2017.-  Chiesi and Richi Social Entrepeneurs have made public today the name of the...
See more